vs
Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and FIBROGEN INC (KYNB). Click either name above to swap in a different company.
FIBROGEN INC is the larger business by last-quarter revenue ($25.4M vs $20.3M, roughly 1.3× Ispire Technology Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -129.8%, a 97.3% gap on every dollar of revenue. On growth, FIBROGEN INC posted the faster year-over-year revenue change (-29.9% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-59.3M). Over the past eight quarters, FIBROGEN INC's revenue compounded faster (-7.8% CAGR vs -17.8%).
Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
ISPR vs KYNB — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $20.3M | $25.4M |
| Net Profit | $-6.6M | $-32.9M |
| Gross Margin | 17.1% | 15.9% |
| Operating Margin | -33.9% | -193.9% |
| Net Margin | -32.5% | -129.8% |
| Revenue YoY | -51.5% | -29.9% |
| Net Profit YoY | 17.4% | 57.1% |
| EPS (diluted) | $-0.12 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.3M | — | ||
| Q3 25 | $30.4M | — | ||
| Q2 25 | $20.1M | — | ||
| Q1 25 | $26.2M | — | ||
| Q4 24 | $41.8M | — | ||
| Q3 24 | $39.3M | — | ||
| Q2 24 | $37.3M | — | ||
| Q1 24 | $30.0M | $25.4M |
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-14.8M | — | ||
| Q1 25 | $-10.9M | — | ||
| Q4 24 | $-8.0M | — | ||
| Q3 24 | $-5.6M | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-5.9M | $-32.9M |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 18.2% | — | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | 19.5% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.4% | 15.9% |
| Q4 25 | -33.9% | — | ||
| Q3 25 | -8.9% | — | ||
| Q2 25 | -72.7% | — | ||
| Q1 25 | -40.4% | — | ||
| Q4 24 | -17.6% | — | ||
| Q3 24 | -13.4% | — | ||
| Q2 24 | -9.2% | — | ||
| Q1 24 | -18.8% | -193.9% |
| Q4 25 | -32.5% | — | ||
| Q3 25 | -10.7% | — | ||
| Q2 25 | -73.4% | — | ||
| Q1 25 | -41.5% | — | ||
| Q4 24 | -19.1% | — | ||
| Q3 24 | -14.2% | — | ||
| Q2 24 | -9.4% | — | ||
| Q1 24 | -19.7% | -129.8% |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.26 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $-0.11 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.6M | $177.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-7.7M | $-228.1M |
| Total Assets | $84.4M | $365.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.6M | — | ||
| Q3 25 | $22.7M | — | ||
| Q2 25 | $24.4M | — | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $34.4M | — | ||
| Q3 24 | $37.7M | — | ||
| Q2 24 | $35.1M | — | ||
| Q1 24 | $39.5M | $177.6M |
| Q4 25 | $-7.7M | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $604.7K | — | ||
| Q1 25 | $14.8M | — | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $30.7M | — | ||
| Q2 24 | $34.5M | — | ||
| Q1 24 | $35.9M | $-228.1M |
| Q4 25 | $84.4M | — | ||
| Q3 25 | $96.4M | — | ||
| Q2 25 | $102.2M | — | ||
| Q1 25 | $115.7M | — | ||
| Q4 24 | $132.0M | — | ||
| Q3 24 | $129.0M | — | ||
| Q2 24 | $122.6M | — | ||
| Q1 24 | $108.0M | $365.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $-59.3M |
| Free Cash FlowOCF − Capex | $-4.0M | $-59.3M |
| FCF MarginFCF / Revenue | -19.9% | -233.9% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.2M | $-274.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-12.5M | — | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $3.4M | $-59.3M |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $-12.7M | — | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q1 24 | $3.3M | $-59.3M |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -3.9% | — | ||
| Q2 25 | 18.6% | — | ||
| Q1 25 | -48.4% | — | ||
| Q4 24 | -7.7% | — | ||
| Q3 24 | 8.5% | — | ||
| Q2 24 | -5.9% | — | ||
| Q1 24 | 10.9% | -233.9% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.3% | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ISPR
Segment breakdown not available.
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
